nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—TNF—multiple sclerosis	0.422	1	CbGaD
Pomalidomide—PTGS2—Triamcinolone—multiple sclerosis	0.0612	0.17	CbGbCtD
Pomalidomide—PTGS2—Betamethasone—multiple sclerosis	0.0525	0.146	CbGbCtD
Pomalidomide—PTGS2—Dexamethasone—multiple sclerosis	0.0306	0.0849	CbGbCtD
Pomalidomide—ABCB1—Methylprednisolone—multiple sclerosis	0.0266	0.074	CbGbCtD
Pomalidomide—CYP3A4—Fingolimod—multiple sclerosis	0.0248	0.0688	CbGbCtD
Pomalidomide—ABCB1—Mitoxantrone—multiple sclerosis	0.0194	0.054	CbGbCtD
Pomalidomide—ABCB1—Betamethasone—multiple sclerosis	0.0173	0.0481	CbGbCtD
Pomalidomide—ABCB1—Prednisolone—multiple sclerosis	0.0171	0.0475	CbGbCtD
Pomalidomide—ABCB1—Prednisone—multiple sclerosis	0.0161	0.0449	CbGbCtD
Pomalidomide—CYP3A4—Methylprednisolone—multiple sclerosis	0.016	0.0444	CbGbCtD
Pomalidomide—CYP3A4—Triamcinolone—multiple sclerosis	0.0121	0.0336	CbGbCtD
Pomalidomide—CYP3A4—Mitoxantrone—multiple sclerosis	0.0116	0.0324	CbGbCtD
Pomalidomide—CYP3A4—Betamethasone—multiple sclerosis	0.0104	0.0288	CbGbCtD
Pomalidomide—CYP3A4—Prednisolone—multiple sclerosis	0.0102	0.0285	CbGbCtD
Pomalidomide—ABCB1—Dexamethasone—multiple sclerosis	0.0101	0.028	CbGbCtD
Pomalidomide—CYP3A4—Prednisone—multiple sclerosis	0.00967	0.0269	CbGbCtD
Pomalidomide—ABCB1—Methotrexate—multiple sclerosis	0.0081	0.0225	CbGbCtD
Pomalidomide—CYP3A4—Dexamethasone—multiple sclerosis	0.00604	0.0168	CbGbCtD
Pomalidomide—Thalidomide—TNF—multiple sclerosis	0.00147	1	CrCbGaD
Pomalidomide—PTGS2—Fluocinonide—Methylprednisolone—multiple sclerosis	0.000495	0.159	CbGdCrCtD
Pomalidomide—PTGS2—Fluocinonide—Betamethasone—multiple sclerosis	0.000487	0.156	CbGdCrCtD
Pomalidomide—PTGS2—Fluocinonide—Dexamethasone—multiple sclerosis	0.000487	0.156	CbGdCrCtD
Pomalidomide—PTGS2—leg—multiple sclerosis	0.000478	0.144	CbGeAlD
Pomalidomide—PTGS2—Fluocinonide—Triamcinolone—multiple sclerosis	0.000476	0.153	CbGdCrCtD
Pomalidomide—CRBN—retina—multiple sclerosis	0.000395	0.119	CbGeAlD
Pomalidomide—PTGS2—Fluticasone Propionate—Methylprednisolone—multiple sclerosis	0.000299	0.0957	CbGdCrCtD
Pomalidomide—PTGS2—Fluticasone Propionate—Dexamethasone—multiple sclerosis	0.000294	0.0942	CbGdCrCtD
Pomalidomide—PTGS2—Fluticasone Propionate—Betamethasone—multiple sclerosis	0.000294	0.0942	CbGdCrCtD
Pomalidomide—PTGS2—Fluticasone Propionate—Triamcinolone—multiple sclerosis	0.000287	0.0921	CbGdCrCtD
Pomalidomide—CRBN—medulla oblongata—multiple sclerosis	0.000285	0.0858	CbGeAlD
Pomalidomide—CRBN—midbrain—multiple sclerosis	0.000261	0.0784	CbGeAlD
Pomalidomide—CRBN—spinal cord—multiple sclerosis	0.000254	0.0765	CbGeAlD
Pomalidomide—CRBN—nervous system—multiple sclerosis	0.000214	0.0645	CbGeAlD
Pomalidomide—CRBN—central nervous system—multiple sclerosis	0.000206	0.0621	CbGeAlD
Pomalidomide—CRBN—cerebellum—multiple sclerosis	0.000202	0.0607	CbGeAlD
Pomalidomide—Hypokalaemia—Prednisone—multiple sclerosis	0.000195	0.00157	CcSEcCtD
Pomalidomide—Leukopenia—Mitoxantrone—multiple sclerosis	0.000194	0.00156	CcSEcCtD
Pomalidomide—Weight increased—Dexamethasone—multiple sclerosis	0.000193	0.00156	CcSEcCtD
Pomalidomide—Weight increased—Betamethasone—multiple sclerosis	0.000193	0.00156	CcSEcCtD
Pomalidomide—Asthenia—Cladribine—multiple sclerosis	0.000193	0.00155	CcSEcCtD
Pomalidomide—Weight decreased—Betamethasone—multiple sclerosis	0.000192	0.00155	CcSEcCtD
Pomalidomide—Weight decreased—Dexamethasone—multiple sclerosis	0.000192	0.00155	CcSEcCtD
Pomalidomide—Hyperglycaemia—Dexamethasone—multiple sclerosis	0.000192	0.00154	CcSEcCtD
Pomalidomide—Hyperglycaemia—Betamethasone—multiple sclerosis	0.000192	0.00154	CcSEcCtD
Pomalidomide—Pruritus—Cladribine—multiple sclerosis	0.00019	0.00153	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Prednisone—multiple sclerosis	0.000189	0.00152	CcSEcCtD
Pomalidomide—Muscular weakness—Prednisone—multiple sclerosis	0.000189	0.00152	CcSEcCtD
Pomalidomide—Cough—Mitoxantrone—multiple sclerosis	0.000189	0.00152	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.000188	0.00152	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Dexamethasone—multiple sclerosis	0.000186	0.0015	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Betamethasone—multiple sclerosis	0.000186	0.0015	CcSEcCtD
Pomalidomide—Arthralgia—Mitoxantrone—multiple sclerosis	0.000184	0.00148	CcSEcCtD
Pomalidomide—Connective tissue disorder—Methylprednisolone—multiple sclerosis	0.000184	0.00148	CcSEcCtD
Pomalidomide—Diarrhoea—Cladribine—multiple sclerosis	0.000184	0.00148	CcSEcCtD
Pomalidomide—Anxiety—Mitoxantrone—multiple sclerosis	0.000183	0.00148	CcSEcCtD
Pomalidomide—Feeling abnormal—Azathioprine—multiple sclerosis	0.00018	0.00145	CcSEcCtD
Pomalidomide—Confusional state—Mitoxantrone—multiple sclerosis	0.000178	0.00143	CcSEcCtD
Pomalidomide—Dizziness—Cladribine—multiple sclerosis	0.000178	0.00143	CcSEcCtD
Pomalidomide—Infection—Mitoxantrone—multiple sclerosis	0.000175	0.00141	CcSEcCtD
Pomalidomide—Cardiac disorder—Methylprednisolone—multiple sclerosis	0.000174	0.0014	CcSEcCtD
Pomalidomide—Neutropenia—Prednisone—multiple sclerosis	0.000173	0.00139	CcSEcCtD
Pomalidomide—Thrombocytopenia—Mitoxantrone—multiple sclerosis	0.000173	0.00139	CcSEcCtD
Pomalidomide—Body temperature increased—Azathioprine—multiple sclerosis	0.000173	0.00139	CcSEcCtD
Pomalidomide—Skin disorder—Mitoxantrone—multiple sclerosis	0.000171	0.00138	CcSEcCtD
Pomalidomide—Vomiting—Cladribine—multiple sclerosis	0.000171	0.00138	CcSEcCtD
Pomalidomide—Hyperhidrosis—Mitoxantrone—multiple sclerosis	0.000171	0.00138	CcSEcCtD
Pomalidomide—Angiopathy—Methylprednisolone—multiple sclerosis	0.00017	0.00137	CcSEcCtD
Pomalidomide—Rash—Cladribine—multiple sclerosis	0.000169	0.00136	CcSEcCtD
Pomalidomide—Dermatitis—Cladribine—multiple sclerosis	0.000169	0.00136	CcSEcCtD
Pomalidomide—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.000169	0.00136	CcSEcCtD
Pomalidomide—Weight increased—Prednisone—multiple sclerosis	0.000168	0.00136	CcSEcCtD
Pomalidomide—Headache—Cladribine—multiple sclerosis	0.000168	0.00136	CcSEcCtD
Pomalidomide—Weight decreased—Prednisone—multiple sclerosis	0.000167	0.00135	CcSEcCtD
Pomalidomide—Hyperglycaemia—Prednisone—multiple sclerosis	0.000167	0.00135	CcSEcCtD
Pomalidomide—Mental disorder—Methylprednisolone—multiple sclerosis	0.000164	0.00132	CcSEcCtD
Pomalidomide—CRBN—brain—multiple sclerosis	0.000164	0.0493	CbGeAlD
Pomalidomide—Malnutrition—Methylprednisolone—multiple sclerosis	0.000163	0.00131	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Prednisone—multiple sclerosis	0.000162	0.0013	CcSEcCtD
Pomalidomide—Breast disorder—Methotrexate—multiple sclerosis	0.000162	0.0013	CcSEcCtD
Pomalidomide—Hypersensitivity—Azathioprine—multiple sclerosis	0.000161	0.0013	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	0.000161	0.0013	CcSEcCtD
Pomalidomide—Nausea—Cladribine—multiple sclerosis	0.000159	0.00129	CcSEcCtD
Pomalidomide—Vertigo—Prednisolone—multiple sclerosis	0.000159	0.00128	CcSEcCtD
Pomalidomide—Back pain—Triamcinolone—multiple sclerosis	0.000158	0.00127	CcSEcCtD
Pomalidomide—Dyspnoea—Mitoxantrone—multiple sclerosis	0.000157	0.00127	CcSEcCtD
Pomalidomide—Angiopathy—Dexamethasone—multiple sclerosis	0.000154	0.00124	CcSEcCtD
Pomalidomide—Angiopathy—Betamethasone—multiple sclerosis	0.000154	0.00124	CcSEcCtD
Pomalidomide—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000153	0.00124	CcSEcCtD
Pomalidomide—Fatigue—Mitoxantrone—multiple sclerosis	0.000152	0.00123	CcSEcCtD
Pomalidomide—Pain—Mitoxantrone—multiple sclerosis	0.000151	0.00122	CcSEcCtD
Pomalidomide—Constipation—Mitoxantrone—multiple sclerosis	0.000151	0.00122	CcSEcCtD
Pomalidomide—Diarrhoea—Azathioprine—multiple sclerosis	0.000149	0.0012	CcSEcCtD
Pomalidomide—Pancytopenia—Methotrexate—multiple sclerosis	0.000147	0.00118	CcSEcCtD
Pomalidomide—Vertigo—Triamcinolone—multiple sclerosis	0.000147	0.00118	CcSEcCtD
Pomalidomide—Vertigo—Methylprednisolone—multiple sclerosis	0.000146	0.00118	CcSEcCtD
Pomalidomide—Connective tissue disorder—Prednisone—multiple sclerosis	0.000146	0.00117	CcSEcCtD
Pomalidomide—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000145	0.00117	CcSEcCtD
Pomalidomide—Neutropenia—Methotrexate—multiple sclerosis	0.000145	0.00117	CcSEcCtD
Pomalidomide—Dizziness—Azathioprine—multiple sclerosis	0.000144	0.00116	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Methotrexate—multiple sclerosis	0.000144	0.00116	CcSEcCtD
Pomalidomide—Cough—Triamcinolone—multiple sclerosis	0.000142	0.00115	CcSEcCtD
Pomalidomide—Hyperhidrosis—Prednisolone—multiple sclerosis	0.00014	0.00113	CcSEcCtD
Pomalidomide—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000139	0.00112	CcSEcCtD
Pomalidomide—Vomiting—Azathioprine—multiple sclerosis	0.000139	0.00112	CcSEcCtD
Pomalidomide—Pneumonia—Methotrexate—multiple sclerosis	0.000139	0.00112	CcSEcCtD
Pomalidomide—Arthralgia—Methylprednisolone—multiple sclerosis	0.000139	0.00112	CcSEcCtD
Pomalidomide—Anxiety—Methylprednisolone—multiple sclerosis	0.000138	0.00111	CcSEcCtD
Pomalidomide—Infestation NOS—Methotrexate—multiple sclerosis	0.000138	0.00111	CcSEcCtD
Pomalidomide—Infestation—Methotrexate—multiple sclerosis	0.000138	0.00111	CcSEcCtD
Pomalidomide—Rash—Azathioprine—multiple sclerosis	0.000138	0.00111	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000138	0.00111	CcSEcCtD
Pomalidomide—Dermatitis—Azathioprine—multiple sclerosis	0.000138	0.00111	CcSEcCtD
Pomalidomide—Headache—Azathioprine—multiple sclerosis	0.000137	0.0011	CcSEcCtD
Pomalidomide—Renal failure—Methotrexate—multiple sclerosis	0.000136	0.00109	CcSEcCtD
Pomalidomide—Angiopathy—Prednisone—multiple sclerosis	0.000134	0.00108	CcSEcCtD
Pomalidomide—Confusional state—Methylprednisolone—multiple sclerosis	0.000134	0.00108	CcSEcCtD
Pomalidomide—Vertigo—Dexamethasone—multiple sclerosis	0.000133	0.00107	CcSEcCtD
Pomalidomide—Vertigo—Betamethasone—multiple sclerosis	0.000133	0.00107	CcSEcCtD
Pomalidomide—Infection—Triamcinolone—multiple sclerosis	0.000132	0.00107	CcSEcCtD
Pomalidomide—Infection—Methylprednisolone—multiple sclerosis	0.000132	0.00106	CcSEcCtD
Pomalidomide—Insomnia—Prednisolone—multiple sclerosis	0.000131	0.00106	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.00013	0.00105	CcSEcCtD
Pomalidomide—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.00013	0.00105	CcSEcCtD
Pomalidomide—Epistaxis—Methotrexate—multiple sclerosis	0.00013	0.00105	CcSEcCtD
Pomalidomide—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.00013	0.00105	CcSEcCtD
Pomalidomide—Mental disorder—Prednisone—multiple sclerosis	0.00013	0.00105	CcSEcCtD
Pomalidomide—Nausea—Azathioprine—multiple sclerosis	0.00013	0.00105	CcSEcCtD
Pomalidomide—Skin disorder—Methylprednisolone—multiple sclerosis	0.000129	0.00104	CcSEcCtD
Pomalidomide—Malnutrition—Prednisone—multiple sclerosis	0.000129	0.00104	CcSEcCtD
Pomalidomide—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000129	0.00104	CcSEcCtD
Pomalidomide—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000128	0.00104	CcSEcCtD
Pomalidomide—Asthenia—Mitoxantrone—multiple sclerosis	0.000127	0.00102	CcSEcCtD
Pomalidomide—Anxiety—Betamethasone—multiple sclerosis	0.000126	0.00101	CcSEcCtD
Pomalidomide—Anxiety—Dexamethasone—multiple sclerosis	0.000126	0.00101	CcSEcCtD
Pomalidomide—Pain—Prednisolone—multiple sclerosis	0.000124	0.000998	CcSEcCtD
Pomalidomide—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000122	0.000985	CcSEcCtD
Pomalidomide—Urethral disorder—Methotrexate—multiple sclerosis	0.000121	0.000978	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000121	0.000978	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000121	0.000976	CcSEcCtD
Pomalidomide—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000121	0.000973	CcSEcCtD
Pomalidomide—Insomnia—Triamcinolone—multiple sclerosis	0.00012	0.000971	CcSEcCtD
Pomalidomide—Insomnia—Methylprednisolone—multiple sclerosis	0.00012	0.000969	CcSEcCtD
Pomalidomide—Infection—Dexamethasone—multiple sclerosis	0.00012	0.000967	CcSEcCtD
Pomalidomide—Infection—Betamethasone—multiple sclerosis	0.00012	0.000967	CcSEcCtD
Pomalidomide—Feeling abnormal—Prednisolone—multiple sclerosis	0.000119	0.000962	CcSEcCtD
Pomalidomide—Anaemia—Prednisone—multiple sclerosis	0.000119	0.00096	CcSEcCtD
Pomalidomide—Dyspnoea—Triamcinolone—multiple sclerosis	0.000119	0.000957	CcSEcCtD
Pomalidomide—Nervous system disorder—Betamethasone—multiple sclerosis	0.000118	0.000955	CcSEcCtD
Pomalidomide—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000118	0.000955	CcSEcCtD
Pomalidomide—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000118	0.000953	CcSEcCtD
Pomalidomide—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000118	0.000953	CcSEcCtD
Pomalidomide—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000117	0.000941	CcSEcCtD
Pomalidomide—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000117	0.000941	CcSEcCtD
Pomalidomide—Vertigo—Prednisone—multiple sclerosis	0.000116	0.000934	CcSEcCtD
Pomalidomide—TNF—amb2 Integrin signaling—IL6—multiple sclerosis	0.000115	0.00134	CbGpPWpGaD
Pomalidomide—Cardiac disorder—Methotrexate—multiple sclerosis	0.000115	0.000926	CcSEcCtD
Pomalidomide—Fatigue—Triamcinolone—multiple sclerosis	0.000115	0.000925	CcSEcCtD
Pomalidomide—Fatigue—Methylprednisolone—multiple sclerosis	0.000115	0.000923	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	0.000114	0.00133	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CCR2—multiple sclerosis	0.000114	0.00133	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	0.000114	0.00133	CbGpPWpGaD
Pomalidomide—Pain—Triamcinolone—multiple sclerosis	0.000114	0.000918	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—CD28—multiple sclerosis	0.000114	0.00132	CbGpPWpGaD
Pomalidomide—Angiopathy—Methotrexate—multiple sclerosis	0.000112	0.000905	CcSEcCtD
Pomalidomide—Vomiting—Mitoxantrone—multiple sclerosis	0.000112	0.000904	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	0.000112	0.0013	CbGpPWpGaD
Pomalidomide—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000112	0.000899	CcSEcCtD
Pomalidomide—Rash—Mitoxantrone—multiple sclerosis	0.000111	0.000897	CcSEcCtD
Pomalidomide—TNF—TNF alpha Signaling Pathway—CCL2—multiple sclerosis	0.000111	0.00129	CbGpPWpGaD
Pomalidomide—Dermatitis—Mitoxantrone—multiple sclerosis	0.000111	0.000896	CcSEcCtD
Pomalidomide—Chills—Methotrexate—multiple sclerosis	0.000111	0.000895	CcSEcCtD
Pomalidomide—TNF—Ceramide signaling pathway—MYC—multiple sclerosis	0.000111	0.00129	CbGpPWpGaD
Pomalidomide—Headache—Mitoxantrone—multiple sclerosis	0.000111	0.000891	CcSEcCtD
Pomalidomide—TNF—SIDS Susceptibility Pathways—BDNF—multiple sclerosis	0.00011	0.00128	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—CD80—multiple sclerosis	0.00011	0.00128	CbGpPWpGaD
Pomalidomide—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.00011	0.000887	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.00011	0.000887	CcSEcCtD
Pomalidomide—TNF—Folate Metabolism—IL1B—multiple sclerosis	0.00011	0.00128	CbGpPWpGaD
Pomalidomide—Arthralgia—Prednisone—multiple sclerosis	0.00011	0.000885	CcSEcCtD
Pomalidomide—Feeling abnormal—Triamcinolone—multiple sclerosis	0.00011	0.000884	CcSEcCtD
Pomalidomide—TNF—Folate Metabolism—IL2—multiple sclerosis	0.00011	0.00128	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—IL2—multiple sclerosis	0.00011	0.00128	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000109	0.000882	CcSEcCtD
Pomalidomide—Anxiety—Prednisone—multiple sclerosis	0.000109	0.000882	CcSEcCtD
Pomalidomide—TNF—Adipogenesis—FAS—multiple sclerosis	0.000109	0.00127	CbGpPWpGaD
Pomalidomide—Insomnia—Betamethasone—multiple sclerosis	0.000109	0.000881	CcSEcCtD
Pomalidomide—Insomnia—Dexamethasone—multiple sclerosis	0.000109	0.000881	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000109	0.000879	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—IL12B—multiple sclerosis	0.000109	0.00127	CbGpPWpGaD
Pomalidomide—Mental disorder—Methotrexate—multiple sclerosis	0.000108	0.000874	CcSEcCtD
Pomalidomide—TNF—TGF-beta Receptor Signaling—STAT3—multiple sclerosis	0.000108	0.00126	CbGpPWpGaD
Pomalidomide—TNF—Ceramide signaling pathway—MAPK1—multiple sclerosis	0.000108	0.00126	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—HLA-DPB1—multiple sclerosis	0.000108	0.00126	CbGpPWpGaD
Pomalidomide—PTGS2—Overview of nanoparticle effects—IL6—multiple sclerosis	0.000108	0.00126	CbGpPWpGaD
Pomalidomide—Malnutrition—Methotrexate—multiple sclerosis	0.000108	0.000868	CcSEcCtD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—SPP1—multiple sclerosis	0.000107	0.00125	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—ALB—multiple sclerosis	0.000107	0.00125	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—CYP24A1—multiple sclerosis	0.000107	0.00125	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—CYP27B1—multiple sclerosis	0.000107	0.00125	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—IFNG—multiple sclerosis	0.000107	0.00124	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Prednisolone—multiple sclerosis	0.000107	0.00086	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—TLR4—multiple sclerosis	0.000106	0.00124	CbGpPWpGaD
Pomalidomide—CYP1A2—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000106	0.00123	CbGpPWpGaD
Pomalidomide—CYP1A2—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000106	0.00123	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL10—multiple sclerosis	0.000105	0.00123	CbGpPWpGaD
Pomalidomide—Body temperature increased—Triamcinolone—multiple sclerosis	0.000105	0.000848	CcSEcCtD
Pomalidomide—Decreased appetite—Dexamethasone—multiple sclerosis	0.000105	0.000847	CcSEcCtD
Pomalidomide—Decreased appetite—Betamethasone—multiple sclerosis	0.000105	0.000847	CcSEcCtD
Pomalidomide—Nausea—Mitoxantrone—multiple sclerosis	0.000105	0.000845	CcSEcCtD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—MAPK1—multiple sclerosis	0.000105	0.00122	CbGpPWpGaD
Pomalidomide—Infection—Prednisone—multiple sclerosis	0.000105	0.000843	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000104	0.000841	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000104	0.000841	CcSEcCtD
Pomalidomide—Back pain—Methotrexate—multiple sclerosis	0.000104	0.00084	CcSEcCtD
Pomalidomide—Fatigue—Dexamethasone—multiple sclerosis	0.000104	0.00084	CcSEcCtD
Pomalidomide—Fatigue—Betamethasone—multiple sclerosis	0.000104	0.00084	CcSEcCtD
Pomalidomide—TNF—MAPK Signaling Pathway—BDNF—multiple sclerosis	0.000104	0.00121	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—CD40—multiple sclerosis	0.000104	0.00121	CbGpPWpGaD
Pomalidomide—Pain—Betamethasone—multiple sclerosis	0.000103	0.000833	CcSEcCtD
Pomalidomide—Pain—Dexamethasone—multiple sclerosis	0.000103	0.000833	CcSEcCtD
Pomalidomide—Nervous system disorder—Prednisone—multiple sclerosis	0.000103	0.000832	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—CTLA4—multiple sclerosis	0.000102	0.00119	CbGpPWpGaD
Pomalidomide—TNF—IL23-mediated signaling events—IL6—multiple sclerosis	0.000102	0.00119	CbGpPWpGaD
Pomalidomide—Skin disorder—Prednisone—multiple sclerosis	0.000102	0.000824	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—ICAM1—multiple sclerosis	0.000102	0.00119	CbGpPWpGaD
Pomalidomide—Hyperhidrosis—Prednisone—multiple sclerosis	0.000102	0.00082	CcSEcCtD
Pomalidomide—TNF—TGF-beta Receptor Signaling—TGFB1—multiple sclerosis	0.0001	0.00117	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—MAPK1—multiple sclerosis	9.99e-05	0.00116	CbGpPWpGaD
Pomalidomide—Anaemia—Methotrexate—multiple sclerosis	9.96e-05	0.000803	CcSEcCtD
Pomalidomide—Feeling abnormal—Betamethasone—multiple sclerosis	9.95e-05	0.000802	CcSEcCtD
Pomalidomide—Feeling abnormal—Dexamethasone—multiple sclerosis	9.95e-05	0.000802	CcSEcCtD
Pomalidomide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	9.9e-05	0.00115	CbGpPWpGaD
Pomalidomide—TNF—Cardiac Hypertrophic Response—TGFB1—multiple sclerosis	9.89e-05	0.00115	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Triamcinolone—multiple sclerosis	9.81e-05	0.000791	CcSEcCtD
Pomalidomide—TNF—Selenium Micronutrient Network—IFNG—multiple sclerosis	9.8e-05	0.00114	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Methylprednisolone—multiple sclerosis	9.79e-05	0.000789	CcSEcCtD
Pomalidomide—TNF—Cardiac Hypertrophic Response—MAPK1—multiple sclerosis	9.7e-05	0.00113	CbGpPWpGaD
Pomalidomide—Vertigo—Methotrexate—multiple sclerosis	9.68e-05	0.00078	CcSEcCtD
Pomalidomide—Leukopenia—Methotrexate—multiple sclerosis	9.64e-05	0.000777	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Prednisone—multiple sclerosis	9.58e-05	0.000773	CcSEcCtD
Pomalidomide—Dizziness—Prednisolone—multiple sclerosis	9.57e-05	0.000772	CcSEcCtD
Pomalidomide—Asthenia—Triamcinolone—multiple sclerosis	9.55e-05	0.00077	CcSEcCtD
Pomalidomide—Body temperature increased—Dexamethasone—multiple sclerosis	9.55e-05	0.00077	CcSEcCtD
Pomalidomide—Body temperature increased—Betamethasone—multiple sclerosis	9.55e-05	0.00077	CcSEcCtD
Pomalidomide—Asthenia—Methylprednisolone—multiple sclerosis	9.53e-05	0.000768	CcSEcCtD
Pomalidomide—TNF—Alzheimers Disease—IL1B—multiple sclerosis	9.53e-05	0.00111	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—IL1B—multiple sclerosis	9.53e-05	0.00111	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—multiple sclerosis	9.52e-05	0.00111	CbGpPWpGaD
Pomalidomide—Insomnia—Prednisone—multiple sclerosis	9.51e-05	0.000767	CcSEcCtD
Pomalidomide—PTGS2—Spinal Cord Injury—CXCL10—multiple sclerosis	9.5e-05	0.00111	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—FAS—multiple sclerosis	9.5e-05	0.00111	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—IL2—multiple sclerosis	9.49e-05	0.0011	CbGpPWpGaD
Pomalidomide—Pruritus—Triamcinolone—multiple sclerosis	9.42e-05	0.000759	CcSEcCtD
Pomalidomide—Cough—Methotrexate—multiple sclerosis	9.4e-05	0.000758	CcSEcCtD
Pomalidomide—Pruritus—Methylprednisolone—multiple sclerosis	9.4e-05	0.000758	CcSEcCtD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	9.39e-05	0.00109	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	9.36e-05	0.00109	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—TLR4—multiple sclerosis	9.32e-05	0.00108	CbGpPWpGaD
Pomalidomide—TNF—TWEAK Signaling Pathway—IL6—multiple sclerosis	9.25e-05	0.00108	CbGpPWpGaD
Pomalidomide—Arthralgia—Methotrexate—multiple sclerosis	9.17e-05	0.000739	CcSEcCtD
Pomalidomide—Decreased appetite—Prednisone—multiple sclerosis	9.14e-05	0.000737	CcSEcCtD
Pomalidomide—Rash—Prednisolone—multiple sclerosis	9.13e-05	0.000736	CcSEcCtD
Pomalidomide—Dermatitis—Prednisolone—multiple sclerosis	9.12e-05	0.000735	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—CCL2—multiple sclerosis	9.11e-05	0.00106	CbGpPWpGaD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	9.11e-05	0.000734	CcSEcCtD
Pomalidomide—Diarrhoea—Methylprednisolone—multiple sclerosis	9.09e-05	0.000733	CcSEcCtD
Pomalidomide—Fatigue—Prednisone—multiple sclerosis	9.07e-05	0.000731	CcSEcCtD
Pomalidomide—Headache—Prednisolone—multiple sclerosis	9.07e-05	0.000731	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—HLA-DQA1—multiple sclerosis	9.02e-05	0.00105	CbGpPWpGaD
Pomalidomide—Constipation—Prednisone—multiple sclerosis	9e-05	0.000725	CcSEcCtD
Pomalidomide—TNF—MAPK Signaling Pathway—FAS—multiple sclerosis	8.9e-05	0.00104	CbGpPWpGaD
Pomalidomide—Confusional state—Methotrexate—multiple sclerosis	8.86e-05	0.000715	CcSEcCtD
Pomalidomide—Dizziness—Triamcinolone—multiple sclerosis	8.8e-05	0.00071	CcSEcCtD
Pomalidomide—TNF—Signaling events mediated by HDAC Class I—STAT3—multiple sclerosis	8.8e-05	0.00102	CbGpPWpGaD
Pomalidomide—Dizziness—Methylprednisolone—multiple sclerosis	8.78e-05	0.000708	CcSEcCtD
Pomalidomide—TNF—Selenium Micronutrient Network—IL1B—multiple sclerosis	8.74e-05	0.00102	CbGpPWpGaD
Pomalidomide—Infection—Methotrexate—multiple sclerosis	8.73e-05	0.000704	CcSEcCtD
Pomalidomide—Feeling abnormal—Prednisone—multiple sclerosis	8.67e-05	0.000699	CcSEcCtD
Pomalidomide—Asthenia—Betamethasone—multiple sclerosis	8.67e-05	0.000699	CcSEcCtD
Pomalidomide—Asthenia—Dexamethasone—multiple sclerosis	8.67e-05	0.000699	CcSEcCtD
Pomalidomide—Nervous system disorder—Methotrexate—multiple sclerosis	8.62e-05	0.000695	CcSEcCtD
Pomalidomide—Thrombocytopenia—Methotrexate—multiple sclerosis	8.61e-05	0.000694	CcSEcCtD
Pomalidomide—Nausea—Prednisolone—multiple sclerosis	8.6e-05	0.000693	CcSEcCtD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—CD80—multiple sclerosis	8.6e-05	0.001	CbGpPWpGaD
Pomalidomide—Pruritus—Dexamethasone—multiple sclerosis	8.55e-05	0.000689	CcSEcCtD
Pomalidomide—Pruritus—Betamethasone—multiple sclerosis	8.55e-05	0.000689	CcSEcCtD
Pomalidomide—Skin disorder—Methotrexate—multiple sclerosis	8.54e-05	0.000688	CcSEcCtD
Pomalidomide—PTGS2—Spinal Cord Injury—BDNF—multiple sclerosis	8.54e-05	0.000993	CbGpPWpGaD
Pomalidomide—Hyperhidrosis—Methotrexate—multiple sclerosis	8.5e-05	0.000685	CcSEcCtD
Pomalidomide—Vomiting—Triamcinolone—multiple sclerosis	8.46e-05	0.000682	CcSEcCtD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—multiple sclerosis	8.46e-05	0.000985	CbGpPWpGaD
Pomalidomide—Vomiting—Methylprednisolone—multiple sclerosis	8.45e-05	0.000681	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—HLA-DQB1—multiple sclerosis	8.43e-05	0.000981	CbGpPWpGaD
Pomalidomide—Rash—Triamcinolone—multiple sclerosis	8.39e-05	0.000677	CcSEcCtD
Pomalidomide—Dermatitis—Triamcinolone—multiple sclerosis	8.39e-05	0.000676	CcSEcCtD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—MAPK1—multiple sclerosis	8.38e-05	0.000976	CbGpPWpGaD
Pomalidomide—Rash—Methylprednisolone—multiple sclerosis	8.38e-05	0.000675	CcSEcCtD
Pomalidomide—Dermatitis—Methylprednisolone—multiple sclerosis	8.37e-05	0.000675	CcSEcCtD
Pomalidomide—Headache—Triamcinolone—multiple sclerosis	8.34e-05	0.000672	CcSEcCtD
Pomalidomide—Headache—Methylprednisolone—multiple sclerosis	8.32e-05	0.000671	CcSEcCtD
Pomalidomide—Body temperature increased—Prednisone—multiple sclerosis	8.32e-05	0.00067	CcSEcCtD
Pomalidomide—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	8.27e-05	0.000963	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	8.27e-05	0.000963	CbGpPWpGaD
Pomalidomide—Diarrhoea—Betamethasone—multiple sclerosis	8.26e-05	0.000666	CcSEcCtD
Pomalidomide—Diarrhoea—Dexamethasone—multiple sclerosis	8.26e-05	0.000666	CcSEcCtD
Pomalidomide—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	8.16e-05	0.00095	CbGpPWpGaD
Pomalidomide—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	8.16e-05	0.00095	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—CD86—multiple sclerosis	8.12e-05	0.000945	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	8.04e-05	0.000935	CbGpPWpGaD
Pomalidomide—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	8.01e-05	0.000646	CcSEcCtD
Pomalidomide—Dizziness—Betamethasone—multiple sclerosis	7.99e-05	0.000644	CcSEcCtD
Pomalidomide—Dizziness—Dexamethasone—multiple sclerosis	7.99e-05	0.000644	CcSEcCtD
Pomalidomide—PTGS2—Selenium Micronutrient Network—ICAM1—multiple sclerosis	7.96e-05	0.000927	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—CD40LG—multiple sclerosis	7.96e-05	0.000927	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL10—multiple sclerosis	7.96e-05	0.000927	CbGpPWpGaD
Pomalidomide—Insomnia—Methotrexate—multiple sclerosis	7.95e-05	0.000641	CcSEcCtD
Pomalidomide—PTGS2—Spinal Cord Injury—IL4—multiple sclerosis	7.93e-05	0.000923	CbGpPWpGaD
Pomalidomide—TNF—Vitamin B12 Metabolism—IL6—multiple sclerosis	7.92e-05	0.000921	CbGpPWpGaD
Pomalidomide—Nausea—Triamcinolone—multiple sclerosis	7.91e-05	0.000637	CcSEcCtD
Pomalidomide—Nausea—Methylprednisolone—multiple sclerosis	7.89e-05	0.000636	CcSEcCtD
Pomalidomide—Dyspnoea—Methotrexate—multiple sclerosis	7.84e-05	0.000632	CcSEcCtD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—IL1B—multiple sclerosis	7.77e-05	0.000904	CbGpPWpGaD
Pomalidomide—PTGS2—medulla oblongata—multiple sclerosis	7.76e-05	0.0234	CbGeAlD
Pomalidomide—Hypersensitivity—Prednisone—multiple sclerosis	7.75e-05	0.000625	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—IFNG—multiple sclerosis	7.75e-05	0.000902	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL4—multiple sclerosis	7.75e-05	0.000902	CbGpPWpGaD
Pomalidomide—Vomiting—Betamethasone—multiple sclerosis	7.68e-05	0.000619	CcSEcCtD
Pomalidomide—Vomiting—Dexamethasone—multiple sclerosis	7.68e-05	0.000619	CcSEcCtD
Pomalidomide—Decreased appetite—Methotrexate—multiple sclerosis	7.64e-05	0.000616	CcSEcCtD
Pomalidomide—Rash—Dexamethasone—multiple sclerosis	7.62e-05	0.000614	CcSEcCtD
Pomalidomide—Rash—Betamethasone—multiple sclerosis	7.62e-05	0.000614	CcSEcCtD
Pomalidomide—Dermatitis—Betamethasone—multiple sclerosis	7.61e-05	0.000613	CcSEcCtD
Pomalidomide—Dermatitis—Dexamethasone—multiple sclerosis	7.61e-05	0.000613	CcSEcCtD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—STAT3—multiple sclerosis	7.6e-05	0.000885	CbGpPWpGaD
Pomalidomide—Gastrointestinal disorder—Methotrexate—multiple sclerosis	7.59e-05	0.000612	CcSEcCtD
Pomalidomide—Fatigue—Methotrexate—multiple sclerosis	7.58e-05	0.000611	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—HLA-B—multiple sclerosis	7.57e-05	0.000882	CbGpPWpGaD
Pomalidomide—Headache—Dexamethasone—multiple sclerosis	7.57e-05	0.00061	CcSEcCtD
Pomalidomide—Headache—Betamethasone—multiple sclerosis	7.57e-05	0.00061	CcSEcCtD
Pomalidomide—TNF—Developmental Biology—PRNP—multiple sclerosis	7.56e-05	0.00088	CbGpPWpGaD
Pomalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—TGFB1—multiple sclerosis	7.56e-05	0.000879	CbGpPWpGaD
Pomalidomide—Asthenia—Prednisone—multiple sclerosis	7.55e-05	0.000608	CcSEcCtD
Pomalidomide—Pain—Methotrexate—multiple sclerosis	7.52e-05	0.000606	CcSEcCtD
Pomalidomide—Pruritus—Prednisone—multiple sclerosis	7.44e-05	0.0006	CcSEcCtD
Pomalidomide—TNF—Allograft Rejection—TGFB1—multiple sclerosis	7.4e-05	0.000862	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	7.27e-05	0.000847	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	7.27e-05	0.000847	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—MAPK1—multiple sclerosis	7.26e-05	0.000845	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Methotrexate—multiple sclerosis	7.24e-05	0.000584	CcSEcCtD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	7.23e-05	0.000842	CbGpPWpGaD
Pomalidomide—Diarrhoea—Prednisone—multiple sclerosis	7.2e-05	0.00058	CcSEcCtD
Pomalidomide—Nausea—Betamethasone—multiple sclerosis	7.18e-05	0.000578	CcSEcCtD
Pomalidomide—Nausea—Dexamethasone—multiple sclerosis	7.18e-05	0.000578	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—FAS—multiple sclerosis	7.14e-05	0.000831	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—CCL2—multiple sclerosis	7.13e-05	0.000829	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL2RA—multiple sclerosis	7.1e-05	0.000826	CbGpPWpGaD
Pomalidomide—PTGS2—midbrain—multiple sclerosis	7.1e-05	0.0213	CbGeAlD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	7.07e-05	0.000823	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—MYC—multiple sclerosis	7.07e-05	0.000822	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—multiple sclerosis	7.05e-05	0.00082	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—HLA-A—multiple sclerosis	7.02e-05	0.000817	CbGpPWpGaD
Pomalidomide—Dizziness—Prednisone—multiple sclerosis	6.96e-05	0.000561	CcSEcCtD
Pomalidomide—Body temperature increased—Methotrexate—multiple sclerosis	6.95e-05	0.00056	CcSEcCtD
Pomalidomide—PTGS2—spinal cord—multiple sclerosis	6.92e-05	0.0208	CbGeAlD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	6.92e-05	0.000805	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—MAPK1—multiple sclerosis	6.91e-05	0.000804	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—IL1B—multiple sclerosis	6.91e-05	0.000804	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—IL2—multiple sclerosis	6.89e-05	0.000801	CbGpPWpGaD
Pomalidomide—Vomiting—Prednisone—multiple sclerosis	6.69e-05	0.000539	CcSEcCtD
Pomalidomide—ABCB1—retina—multiple sclerosis	6.64e-05	0.02	CbGeAlD
Pomalidomide—PTGS2—Selenium Micronutrient Network—ALB—multiple sclerosis	6.64e-05	0.000773	CbGpPWpGaD
Pomalidomide—Rash—Prednisone—multiple sclerosis	6.63e-05	0.000535	CcSEcCtD
Pomalidomide—Dermatitis—Prednisone—multiple sclerosis	6.63e-05	0.000534	CcSEcCtD
Pomalidomide—Headache—Prednisone—multiple sclerosis	6.59e-05	0.000531	CcSEcCtD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	6.59e-05	0.000767	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TLR4—multiple sclerosis	6.57e-05	0.000764	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—MMP9—multiple sclerosis	6.52e-05	0.000758	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Methotrexate—multiple sclerosis	6.48e-05	0.000522	CcSEcCtD
Pomalidomide—TNF—Folate Metabolism—IL6—multiple sclerosis	6.44e-05	0.00075	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—MAPK1—multiple sclerosis	6.43e-05	0.000748	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—HLA-DRB1—multiple sclerosis	6.41e-05	0.000746	CbGpPWpGaD
Pomalidomide—Asthenia—Methotrexate—multiple sclerosis	6.31e-05	0.000509	CcSEcCtD
Pomalidomide—PTGS2—Spinal Cord Injury—ICAM1—multiple sclerosis	6.3e-05	0.000733	CbGpPWpGaD
Pomalidomide—Nausea—Prednisone—multiple sclerosis	6.25e-05	0.000504	CcSEcCtD
Pomalidomide—Pruritus—Methotrexate—multiple sclerosis	6.22e-05	0.000501	CcSEcCtD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—multiple sclerosis	6.16e-05	0.000717	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—CD4—multiple sclerosis	6.07e-05	0.000707	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL1B—multiple sclerosis	6.06e-05	0.000706	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—IFNG—multiple sclerosis	6.06e-05	0.000705	CbGpPWpGaD
Pomalidomide—Diarrhoea—Methotrexate—multiple sclerosis	6.02e-05	0.000485	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—CD80—multiple sclerosis	5.92e-05	0.000689	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—MAPK1—multiple sclerosis	5.92e-05	0.000689	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—PTPRC—multiple sclerosis	5.88e-05	0.000685	CbGpPWpGaD
Pomalidomide—PTGS2—nervous system—multiple sclerosis	5.83e-05	0.0175	CbGeAlD
Pomalidomide—Dizziness—Methotrexate—multiple sclerosis	5.81e-05	0.000469	CcSEcCtD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	5.81e-05	0.000676	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	5.76e-05	0.000671	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CCL2—multiple sclerosis	5.64e-05	0.000656	CbGpPWpGaD
Pomalidomide—PTGS2—central nervous system—multiple sclerosis	5.62e-05	0.0169	CbGeAlD
Pomalidomide—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	5.6e-05	0.000652	CbGpPWpGaD
Pomalidomide—Vomiting—Methotrexate—multiple sclerosis	5.59e-05	0.000451	CcSEcCtD
Pomalidomide—Rash—Methotrexate—multiple sclerosis	5.54e-05	0.000447	CcSEcCtD
Pomalidomide—Dermatitis—Methotrexate—multiple sclerosis	5.54e-05	0.000446	CcSEcCtD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL1B—multiple sclerosis	5.53e-05	0.000643	CbGpPWpGaD
Pomalidomide—Headache—Methotrexate—multiple sclerosis	5.51e-05	0.000444	CcSEcCtD
Pomalidomide—PTGS2—cerebellum—multiple sclerosis	5.49e-05	0.0165	CbGeAlD
Pomalidomide—PTGS2—Selenium Micronutrient Network—IL1B—multiple sclerosis	5.4e-05	0.000629	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—MYC—multiple sclerosis	5.38e-05	0.000627	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—TGFB1—multiple sclerosis	5.37e-05	0.000625	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—STAT3—multiple sclerosis	5.36e-05	0.000624	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	5.27e-05	0.000614	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—MAPK1—multiple sclerosis	5.27e-05	0.000613	CbGpPWpGaD
Pomalidomide—Nausea—Methotrexate—multiple sclerosis	5.22e-05	0.000421	CcSEcCtD
Pomalidomide—TNF—MAPK Signaling Pathway—IL1B—multiple sclerosis	5.21e-05	0.000606	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	5.14e-05	0.000598	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	5.13e-05	0.000597	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	5.12e-05	0.000596	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—IL6—multiple sclerosis	5.12e-05	0.000596	CbGpPWpGaD
Pomalidomide—CYP3A4—nervous system—multiple sclerosis	5.1e-05	0.0153	CbGeAlD
Pomalidomide—TNF—Adipogenesis—TGFB1—multiple sclerosis	4.97e-05	0.000578	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	4.97e-05	0.000578	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—IL6—multiple sclerosis	4.94e-05	0.000575	CbGpPWpGaD
Pomalidomide—CYP3A4—central nervous system—multiple sclerosis	4.91e-05	0.0148	CbGeAlD
Pomalidomide—ABCB1—medulla oblongata—multiple sclerosis	4.8e-05	0.0144	CbGeAlD
Pomalidomide—PTGS2—Spinal Cord Injury—IFNG—multiple sclerosis	4.79e-05	0.000558	CbGpPWpGaD
Pomalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	4.77e-05	0.000555	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IFNG—multiple sclerosis	4.68e-05	0.000545	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—MAPK1—multiple sclerosis	4.62e-05	0.000538	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—SRM—multiple sclerosis	4.6e-05	0.000535	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—IL6—multiple sclerosis	4.55e-05	0.000529	CbGpPWpGaD
Pomalidomide—CYP1A2—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	4.54e-05	0.000528	CbGpPWpGaD
Pomalidomide—PTGS2—brain—multiple sclerosis	4.46e-05	0.0134	CbGeAlD
Pomalidomide—ABCB1—midbrain—multiple sclerosis	4.39e-05	0.0132	CbGeAlD
Pomalidomide—PTGS2—C-MYB transcription factor network—MYC—multiple sclerosis	4.37e-05	0.000509	CbGpPWpGaD
Pomalidomide—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	4.32e-05	0.000503	CbGpPWpGaD
Pomalidomide—ABCB1—spinal cord—multiple sclerosis	4.28e-05	0.0129	CbGeAlD
Pomalidomide—PTGS2—Spinal Cord Injury—IL1B—multiple sclerosis	4.27e-05	0.000497	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IL2—multiple sclerosis	4.26e-05	0.000496	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL1B—multiple sclerosis	4.18e-05	0.000486	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL2—multiple sclerosis	4.16e-05	0.000484	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	4.12e-05	0.000479	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	4.12e-05	0.000479	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	4.12e-05	0.000479	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—MYC—multiple sclerosis	4.06e-05	0.000472	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—TGFB1—multiple sclerosis	4.05e-05	0.000471	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—IL6—multiple sclerosis	4.05e-05	0.000471	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—MMP9—multiple sclerosis	4.03e-05	0.000469	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	4e-05	0.000466	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	4e-05	0.000465	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	3.99e-05	0.000465	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—MAPK1—multiple sclerosis	3.97e-05	0.000462	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—TNF—multiple sclerosis	3.92e-05	0.000456	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	3.92e-05	0.000456	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—IL6—multiple sclerosis	3.75e-05	0.000436	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	3.73e-05	0.000434	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	3.73e-05	0.000434	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	3.66e-05	0.000426	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	3.65e-05	0.000425	CbGpPWpGaD
Pomalidomide—ABCB1—nervous system—multiple sclerosis	3.61e-05	0.0109	CbGeAlD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	3.58e-05	0.000417	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL6—multiple sclerosis	3.55e-05	0.000413	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—GPC5—multiple sclerosis	3.54e-05	0.000412	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	3.52e-05	0.00041	CbGpPWpGaD
Pomalidomide—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	3.5e-05	0.000408	CbGpPWpGaD
Pomalidomide—ABCB1—central nervous system—multiple sclerosis	3.47e-05	0.0105	CbGeAlD
Pomalidomide—ABCB1—cerebellum—multiple sclerosis	3.4e-05	0.0102	CbGeAlD
Pomalidomide—PTGS2—Spinal Cord Injury—MYC—multiple sclerosis	3.33e-05	0.000388	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TGFB1—multiple sclerosis	3.32e-05	0.000387	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—SRM—multiple sclerosis	3.26e-05	0.000379	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—MAPK1—multiple sclerosis	3.26e-05	0.000379	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—TGFB1—multiple sclerosis	3.25e-05	0.000378	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CYP24A1—multiple sclerosis	3.24e-05	0.000377	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CYP27B1—multiple sclerosis	3.24e-05	0.000377	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL6—multiple sclerosis	3.24e-05	0.000377	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	3.17e-05	0.000368	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—IL6—multiple sclerosis	3.16e-05	0.000368	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	3.16e-05	0.000368	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TNF—multiple sclerosis	3.1e-05	0.000361	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—TNF—multiple sclerosis	3.03e-05	0.000353	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GPC5—multiple sclerosis	2.96e-05	0.000345	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	2.79e-05	0.000325	CbGpPWpGaD
Pomalidomide—ABCB1—brain—multiple sclerosis	2.76e-05	0.0083	CbGeAlD
Pomalidomide—TNF—Developmental Biology—TYK2—multiple sclerosis	2.63e-05	0.000306	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—SRM—multiple sclerosis	2.6e-05	0.000303	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IL6—multiple sclerosis	2.5e-05	0.000291	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—RRM1—multiple sclerosis	2.45e-05	0.000286	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—POMC—multiple sclerosis	2.41e-05	0.000281	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—RPL5—multiple sclerosis	2.3e-05	0.000268	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP27B1—multiple sclerosis	2.3e-05	0.000267	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP24A1—multiple sclerosis	2.3e-05	0.000267	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	2.27e-05	0.000264	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	2.26e-05	0.000263	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	2.22e-05	0.000258	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—SLC11A1—multiple sclerosis	2.2e-05	0.000256	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	2.11e-05	0.000246	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GPC5—multiple sclerosis	2.1e-05	0.000244	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MMP9—multiple sclerosis	2.07e-05	0.000241	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—SRM—multiple sclerosis	2.01e-05	0.000234	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.9e-05	0.000222	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—POMC—multiple sclerosis	1.86e-05	0.000217	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—STAT3—multiple sclerosis	1.84e-05	0.000214	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP27B1—multiple sclerosis	1.83e-05	0.000213	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP24A1—multiple sclerosis	1.83e-05	0.000213	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.79e-05	0.000209	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CD28—multiple sclerosis	1.76e-05	0.000205	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—RRM1—multiple sclerosis	1.74e-05	0.000203	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—TGFB1—multiple sclerosis	1.71e-05	0.000199	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GPC5—multiple sclerosis	1.68e-05	0.000195	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MAPK1—multiple sclerosis	1.68e-05	0.000195	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.64e-05	0.00019	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	1.61e-05	0.000187	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	1.6e-05	0.000186	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	1.57e-05	0.000183	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	1.5e-05	0.000174	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.49e-05	0.000174	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.41e-05	0.000165	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.41e-05	0.000165	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—BCHE—multiple sclerosis	1.41e-05	0.000164	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—RRM1—multiple sclerosis	1.39e-05	0.000162	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.29e-05	0.000151	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—IL6—multiple sclerosis	1.29e-05	0.00015	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CD86—multiple sclerosis	1.26e-05	0.000146	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CCR5—multiple sclerosis	1.11e-05	0.00013	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HLA-A—multiple sclerosis	1.08e-05	0.000126	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.08e-05	0.000125	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.07e-05	0.000125	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—APOE—multiple sclerosis	1.01e-05	0.000118	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.01e-05	0.000117	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—BCHE—multiple sclerosis	9.99e-06	0.000116	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	9.26e-06	0.000108	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CD80—multiple sclerosis	9.16e-06	0.000107	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—APOE—multiple sclerosis	8.48e-06	9.87e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	8.44e-06	9.82e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—BCHE—multiple sclerosis	7.98e-06	9.29e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TYK2—multiple sclerosis	7.73e-06	9e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—POMC—multiple sclerosis	7.29e-06	8.48e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CD4—multiple sclerosis	6.99e-06	8.14e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ALB—multiple sclerosis	6.64e-06	7.73e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—BCHE—multiple sclerosis	6.16e-06	7.17e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—APOE—multiple sclerosis	6.01e-06	7e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—STAT3—multiple sclerosis	5.41e-06	6.3e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—POMC—multiple sclerosis	5.17e-06	6.01e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MYC—multiple sclerosis	5.03e-06	5.85e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TGFB1—multiple sclerosis	5.02e-06	5.84e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MAPK1—multiple sclerosis	4.92e-06	5.73e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—APOE—multiple sclerosis	4.8e-06	5.59e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ALB—multiple sclerosis	4.71e-06	5.48e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—POMC—multiple sclerosis	4.12e-06	4.8e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—IL6—multiple sclerosis	3.78e-06	4.4e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ALB—multiple sclerosis	3.76e-06	4.38e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—APOE—multiple sclerosis	3.7e-06	4.31e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—POMC—multiple sclerosis	3.18e-06	3.7e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ALB—multiple sclerosis	2.9e-06	3.38e-05	CbGpPWpGaD
